Med-Mastodon

0 posts0 participants0 posts today

Giuseppe Michieli<a href="https://mstdn.science/tags/US" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#US</a> <a href="https://mstdn.science/tags/NIH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#NIH</a> <a href="https://mstdn.science/tags/Study" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Study</a> Finds <a href="https://mstdn.science/tags/Tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tecovirimat</a> Was Safe but Did Not Improve <a href="https://mstdn.science/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> Resolution or <a href="https://mstdn.science/tags/Pain" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Pain</a>, <a href="https://www.nih.gov/news-events/news-releases/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.nih.gov/news-events/news-releases/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain</a> <a href="https://mstdn.science/tags/Antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Antiviral</a> drug tecovirimat did not reduce time to lesion <a href="https://mstdn.science/tags/resolution" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#resolution</a> or have an effect on pain among adults with mild to moderate clade II mpox & a low risk of developing severe disease, according to an interim data analysis from international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.

ETIDIoHSource: Emerging Infectious Diseases Journal, <a href="https://wwwnc.cdc.gov/eid/article/30/11/24-1331_article" rel="nofollow noopener noreferrer" target="_blank">https://wwwnc.cdc.gov/eid/article/30/11/24-1331_article</a> Abstract We report a case of persistent disseminated mpox evolving over >6 months in an HIV/hepatitis B virus co-infected patient in France who had <200 CD4+ cells/mm3, pulmonary and hepatic necrotic lesions, persistent viremia, and nasopharyngeal excretion. Clinical outcome was favorable after 90 days of tecovirimat treatment and administration of human vaccinia immunoglobulins.____<a href="https://etidioh.wordpress.com/2024/10/21/mpox-hepatic-and-pulmonary-lesions-in-hiv-hepatitis-b-virus-co-infected-patient-france/" class="" rel="nofollow noopener noreferrer" target="_blank">https://etidioh.wordpress.com/2024/10/21/mpox-hepatic-and-pulmonary-lesions-in-hiv-hepatitis-b-virus-co-infected-patient-france/</a><a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/abstract/" target="_blank">#abstract</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/antivirals-2/" target="_blank">#antivirals</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/france-2/" target="_blank">#france</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/hepatitis-b/" target="_blank">#hepatitisB</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/hivaids/" target="_blank">#HIVAIDS</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/mpox/" target="_blank">#mpox</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/research-2/" target="_blank">#research</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/tecovirimat/" target="_blank">#tecovirimat</a>

ETIDIoHSource: US National Library of Medicine, <a href="https://pubmed.ncbi.nlm.nih.gov/39388389/" rel="nofollow noopener noreferrer" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39388389/</a> Abstract The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.____<a href="https://etidioh.wordpress.com/2024/10/11/notes-from-the-field-mpox-cluster-caused-by-tecovirimat-resistant-monkeypox-virus-five-states-october-2023-february-2024/" class="" rel="nofollow noopener noreferrer" target="_blank">https://etidioh.wordpress.com/2024/10/11/notes-from-the-field-mpox-cluster-caused-by-tecovirimat-resistant-monkeypox-virus-five-states-october-2023-february-2024/</a><a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/abstract/" target="_blank">#abstract</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/antivirals-2/" target="_blank">#antivirals</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/california-2/" target="_blank">#california</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/drugs-resistance/" target="_blank">#drugsResistance</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/mpox/" target="_blank">#mpox</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/research-2/" target="_blank">#research</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/tecovirimat/" target="_blank">#tecovirimat</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/usa/" target="_blank">#USA</a>

Giuseppe MichieliNotes from the Field: <a href="https://mstdn.science/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> <a href="https://mstdn.science/tags/Cluster" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Cluster</a> Caused by <a href="https://mstdn.science/tags/Tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tecovirimat</a> – <a href="https://mstdn.science/tags/Resistant" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Resistant</a> Monkeypox Virus – Five States, October 2023-February 2024Source: US National Library of Medicine, AbstractThe antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners…<a href="https://etidioh.wordpress.com/2024/10/11/notes-from-the-field-mpox-cluster-caused-by-tecovirimat-resistant-monkeypox-virus-five-states-october-2023-february-2024/" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://etidioh.wordpress.com/2024/10/11/notes-from-the-field-mpox-cluster-caused-by-tecovirimat-resistant-monkeypox-virus-five-states-october-2023-february-2024/</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tecovirimat</a> Use under Expanded Access to Treat <a href="https://mstdn.science/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> in <a href="https://mstdn.science/tags/USA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#USA</a>, 2022–2023, NEJM Evidence: <a href="https://evidence.nejm.org/doi/10.1056/EVIDoa2400189" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://evidence.nejm.org/doi/10.1056/EVIDoa2400189</a> Tecovirimat was used extensively. The returned EA-IND data suggest that life-threatening or protracted <a href="https://mstdn.science/tags/infections" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#infections</a> occurred in persons who were severely immunocompromised. <a href="https://mstdn.science/tags/SAEs" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SAEs</a> were not commonly reported. The EA-IND data are not definitive; controlled clinical trial data are essential to elucidating if and how tecovirimat should be used.

Giuseppe Michieli<a href="https://mstdn.science/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> <a href="https://mstdn.science/tags/outbreak" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#outbreak</a> — <a href="https://mstdn.science/tags/tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#tecovirimat</a> <a href="https://mstdn.science/tags/resistance" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#resistance</a>, <a href="https://mstdn.science/tags/management" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#management</a> approaches, and <a href="https://mstdn.science/tags/challenges" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#challenges</a> in <a href="https://mstdn.science/tags/HIV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HIV</a>-endemic regions, Lancet Infect Dis.: <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00591-7/fulltext?rss=yes" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00591-7/fulltext?rss=yes</a> ... while concentrating our efforts on responding to the current outbreak and gaining better insight into shifting MPXV biology in the human host, ensuring access to antivirals—particularly <a href="https://mstdn.science/tags/ART" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#ART</a>—and comprehensive HIV care remains crucial.

Scientific EuropeanMpox Disease: The Antiviral Tecovirimat (TPOXX) Found Ineffective in Clinical Trial The monkeypox virus (MPXV), called so because of its first discovery in monkeys kept in research facility in Denmark, is closely related to variola........... <a href="https://toot.community/tags/antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antiviral</a> <a href="https://toot.community/tags/AntiviralDrug" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#AntiviralDrug</a> <a href="https://toot.community/tags/DRCongo" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#DRCongo</a> <a href="https://toot.community/tags/monkeypox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#monkeypox</a> <a href="https://toot.community/tags/monkeypoxvirus" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#monkeypoxvirus</a> <a href="https://toot.community/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> <a href="https://toot.community/tags/MPXV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#MPXV</a> <a href="https://toot.community/tags/Tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tecovirimat</a> Umesh Prasad <a href="https://www.scientificeuropean.co.uk/medicine/mpox-disease-the-antiviral-tecovirimat-tpoxx-found-ineffective-trial-in-dr-congo/" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.scientificeuropean.co.uk/medicine/mpox-disease-the-antiviral-tecovirimat-tpoxx-found-ineffective-trial-in-dr-congo/</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Antiviral</a> <a href="https://mstdn.science/tags/tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#tecovirimat</a> is safe but {was ineffective in} clade I <a href="https://mstdn.science/tags/mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#mpox</a> <a href="https://mstdn.science/tags/resolution" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#resolution</a> in <a href="https://mstdn.science/tags/DRC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#DRC</a>, US <a href="https://mstdn.science/tags/NIH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#NIH</a>: <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo</a> “These findings are disappointing, but they give us essential information & reinforce need to identify other candidates for mpox while we continue research on tecovirimat use in other populations with mpox,” said NIAID Director J Marrazzo. “We remain committed to developing interventions, including treatments & vax, that can ease devastating mpox burden in C Africa...

Martin Michaelis (he/him)Es ist nicht ganz richtig, dass es keine Medikamente gegen <a href="https://mastodonapp.uk/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> gibt. <a href="https://mastodonapp.uk/tags/Tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tecovirimat</a> wurde aufgrund von Tierstudien, einschließlich der Wirkung gegen Mpox in Makaken, zur Behandlung vom <a href="https://mastodonapp.uk/tags/smallpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#smallpox</a> zugelassen. 1/<a href="https://www.tagesschau.de/wissen/gesundheit/mpox-ausbreitung-afrika-100.html" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.tagesschau.de/wissen/gesundheit/mpox-ausbreitung-afrika-100.html</a>

PLOS BiologyEffect of <a href="https://fediscience.org/tags/tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#tecovirimat</a> in human <a href="https://fediscience.org/tags/mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#mpox</a>. This study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using integrative modeling that combines preclinical & clinical data <a href="https://fediscience.org/tags/PLOSBiology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PLOSBiology</a> <a href="https://plos.io/484IfX6" rel="nofollow noopener noreferrer" target="_blank">https://plos.io/484IfX6</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tecovirimat</a> <a href="https://mstdn.science/tags/Resistance" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Resistance</a> in <a href="https://mstdn.science/tags/Mpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Mpox</a> Patients, <a href="https://mstdn.science/tags/USA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#USA</a>, 2022–2023, Emerg Infect Dis.: <a href="https://wwwnc.cdc.gov/eid/article/29/12/23-1146_article?ACSTrackingID=USCDC_333-DM115592&ACSTrackingLabel=Latest%20Expedited%20Articles%20-%20Emerging%20Infectious%20Diseases%20Journal%20-%20October%2019%2C%202023&deliveryName=USCDC_333-DM115592" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://wwwnc.cdc.gov/eid/article/29/12/23-1146_article?ACSTrackingID=USCDC_333-DM115592&ACSTrackingLabel=Latest%20Expedited%20Articles%20-%20Emerging%20Infectious%20Diseases%20Journal%20-%20October%2019%2C%202023&deliveryName=USCDC_333-DM115592</a> <a href="https://mstdn.science/tags/antivirals" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antivirals</a> <a href="https://mstdn.science/tags/drugs" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#drugs</a> <a href="https://mstdn.science/tags/EIDs" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#EIDs</a>

Thiago CarvalhoGathering real world data on the efficacy of drugs and vaccines used to treat or prevent <a href="https://qoto.org/tags/monkeypox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#monkeypox</a> is vital. Many where developed for <a href="https://qoto.org/tags/smallpox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#smallpox</a> and approved via the FDA's "animal rule", which means that although the safety data is there, the efficacy is essentially unknown. I wrote a bit about this for <a href="https://qoto.org/tags/NatureMedicine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#NatureMedicine</a> in September when looking at the use of the <a href="https://qoto.org/tags/antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antiviral</a> <a href="https://qoto.org/tags/tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#tecovirimat</a> for monkeypox.<a href="https://www.nature.com/articles/d41591-022-00094-0" rel="nofollow noopener noreferrer" target="_blank">https://www.nature.com/articles/d41591-022-00094-0</a>

Thiago Carvalho'We report on the protocolized use of tecovirimat (SIGA Technologies), an antiviral drug with activity against orthopoxviruses (including monkeypox and smallpox),1 under an expanded access program for all patients with monkeypox virus (MPXV) disease in Mbaïki, Central African Republic, between December 2021 and February 2022.2 Included in the study were 14 patients in whom MPXV infection had been diagnosed.'<a href="https://qoto.org/tags/monkeypox" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#monkeypox</a> <a href="https://qoto.org/tags/tecovirimat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#tecovirimat</a> <a href="https://qoto.org/tags/nejm" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#nejm</a> <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2210015?query=featured_home" rel="nofollow noopener noreferrer" target="_blank">https://www.nejm.org/doi/full/10.1056/NEJMc2210015?query=featured_home</a>

Recent searches

Search options

Administered by:

Server stats:

#tecovirimat